In conclusion, this study synthesized IL-2 nanoparticles and combined them with CDK4/6 inhibitors (Palbociclib), resulting in superior tumor suppression in mice without increased toxicity. These findings encourage further exploration of the clinical application of IL-2 and propose a new combination therapy paradigm that could reshape our approach to cancer immunotherapy. Here, CDK4 is linked to cancer.